Release Date: June 30, 2022
Expiration Date: June 30, 2023
Activity Overview
Hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) affects approximately 10% to 20% of allogeneic transplant patients. TA-TMA is difficult to diagnose, as symptoms often mirror those of other thrombotic conditions, and they can lead to multiple organ failure and mortality in these patients. A better understanding of the pathogenesis of TA-TMA and earlier diagnostic strategies can lead to emerging therapies and improved patient outcomes.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 2022 Tandem Meetings of ASTCT & CIBMTR held in April 2022. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with TA-TMA, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Target Audience
This educational program is directed toward hematologists, oncologists, blood and marrow transplant (BMT) specialists, BMT nurses, and other clinicians involved in the treatment of patients with hematologic malignancies.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess current diagnostic criteria for TA-associated TMA and ways to differentiate from other stem cell transplant-associated complications
- Describe the role of dysregulated complement activation in the pathogenesis of TA-associated TMA
- Evaluate the rationale concerning the application of inhibitors of the lectin and other complement pathways, including MASP-2 inhibitors, in the treatment of TA-associated TMA
- Discuss recent clinical trial data concerning the effectiveness of current and emerging therapies in the treatment of TA-TMA
Jeffrey Laurence, MD
Professor of Medicine
Weill Cornell Medicine
New York, NY
Disclosures: Grant/Research Support: Alexion Pharmaceuticals, Jazz Pharmaceuticals, Omeros Corporation; Consultant: Omeros Corporation; Speakers’ Bureau: Alexion Pharmaceuticals.
Mitchell S. Cairo, MD
Chief, Pediatric Hematology, Oncology, and Stem Cell Transplantation
Director, Children and Adolescent Cancer and Blood Diseases Center
Director, WMC Cancer Center
Medical and Scientific Director, WMC Cellular and Tissue Engineering Laboratory
Medical Director, WMC Hematotherapy Program
Associate Chairman, Department of Pediatrics
Professor of Pediatrics
Medicine, Pathology, Microbiology & Immunology, and Cell Biology & Anatomy
Maria Fareri Children’s Hospital
Westchester Medical Center
New York Medical College
Hawthorne, NY
Disclosures: Grant/Research Support: Omeros, Jazz, Servier, Merck & Co., Celularity, BMS, Abbvie; Consultant: Omeros, Jazz, Servier, AstraZeneca, Abbvie, Spectrum, Novartis; Speakers’ Bureau: Jazz, Servier, SOBI, Sanofi, Amgen.
Vincent T. Ho, MD
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Operations, Adult Allogeneic Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Grant/Research Support: Jazz Pharmaceuticals; Consultant: Alexion Pharmaceuticals, AlloVir, Omeros Corporation.
Sonata Jodele, MD
Research Professor of Pediatrics
Division of Bone Marrow Transplantation and Immune Defi ciency
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
Disclosures: Grant/Research Support: Alexion Pharmaceuticals, AlloVir, Omeros Corporation; Consultant: Alexion Pharmaceuticals, Omeros Corporation, SOBI; Other: US patent on eculizumab use in TA-TMA.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with
ineligible companies, with the following exception (Sara Fagerlie, PhD, freelance medical
director: Former Consultant: Adaptive Biotechnologies).
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest resolution process and resolved.